Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (VSTM)
Last verastem, inc. earnings: 10/29 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
verastem.com
Company Research
Source: Business Wire
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $6.88 per share, the closing price of Verastem Oncology’s common stock as reported by Nasdaq on January 6, 2026. The stock options to purchase 73,000 shares of common stock granted to eight new employees and 218,265 restricted stock units granted to nineteen new employees will vest at a rate of twenty-five percent (25%) on the one-year anniversary of the employee’
Show less
Read more
Impact Snapshot
Event Time:
VSTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VSTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VSTM alerts
High impacting Verastem, Inc. news events
Weekly update
A roundup of the hottest topics
VSTM
News
- Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]Seeking Alpha
- Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung CancerBusiness Wire
- Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]Yahoo! Finance
- Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of GrowthBusiness Wire
VSTM
Earnings
- 11/4/25 - Miss
VSTM
Sec Filings
- 1/8/26 - Form 8-K
- 1/8/26 - Form 4
- 1/5/26 - Form SCHEDULE
- VSTM's page on the SEC website